These recommendations are based on JUPITER trial [42] assessing the benefit of statin treatment in apparently healthy persons with hyperlipidemia (LDL-C < 130 mg/dL) but with elevated high-sensitivity CRP levels (hs-CRP ≥ 2 mg/dL). Here, CRP is linked to hyperlipidemia.